Caitong International Asset Management Co., LTD C4 Therapeutics, Inc. Transaction History
Caitong International Asset Management Co., LTD
- $102 Billion
- Q4 2024
A detailed history of Caitong International Asset Management Co., LTD transactions in C4 Therapeutics, Inc. stock. As of the latest transaction made, Caitong International Asset Management Co., LTD holds 15 shares of CCCC stock, worth $47. This represents 0.0% of its overall portfolio holdings.
Number of Shares
15
Previous 15
-0.0%
Holding current value
$47
Previous $54,000
-0.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding CCCC
# of Institutions
124Shares Held
65.2MCall Options Held
544KPut Options Held
30.3K-
Soleus Capital Management, L.P. Greenwich, CT6.98MShares$22.2 Million1.75% of portfolio
-
Lynx1 Capital Management LP San Juan, PR6.85MShares$21.8 Million9.58% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT6.07MShares$19.3 Million0.11% of portfolio
-
Ra Capital Management, L.P. Boston, MA4.88MShares$15.5 Million0.28% of portfolio
-
Black Rock Inc. New York, NY4.55MShares$14.5 Million0.0% of portfolio
About C4 Therapeutics, Inc.
- Ticker CCCC
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 48,913,800
- Market Cap $156M
- Description
- C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins for the treatment of cancer, neurodegenerative conditions, and other diseases. Its lead product candidate is CFT7455, an orally bioavailable MonoDAC degrader of protein that is in Phase 1/2 trial targeting ...